Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 363 clinical trials
featured
A Study to Evaluate INSTILADRIN® in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC- Non muscle invasive bladder cancer

A Study to Evaluate INSTILADRIN® in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC- Non muscle invasive bladder cancer

  • 142 views
  • 08 Nov, 2020
  • 1 location
featured
A multicenter clinical study of the Sonablate® 500 (Sonablate) for the TreAtment of locally Recurrent prostate cancer with HIFU(STAR Trial)

A multicenter clinical study of the Sonablate® 500 (Sonablate) for the TreAtment of locally Recurrent prostate cancer with HIFU(STAR Trial)

  • 196 views
  • 25 Mar, 2021
  • 1 location
Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients

This is an open-label, randomized, multicentric study in patients with high-risk non-muscle invasive bladder cancer who had never received BCG for this disease. The objective is to

neutrophil count
gilbert's syndrome
TURB
atezolizumab
intravesical administration
  • 0 views
  • 07 Apr, 2021
  • 30 locations
Atezolizumab and BCG in High Risk BCG na ve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)

Patients with high-risk non-muscle invasive bladder cancer (NMIBC) are usually managed by transurethral resection of their bladder tumor (TURBT) alone plus additional intravesical therapy to

carcinoma in situ
bladder cancer
transurethral resection
carcinoma of the bladder
expression by immunohistochemistry
  • 0 views
  • 25 Jan, 2021
Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors

This study is to assess the safety and tolerability, and to assess the preliminary clinical benefit of NKTR-214 when combined with pembrolizumab (KEYTRUDA) with or without chemotherapy. The study is comprised of two groups; dose optimization and dose expansion cohorts. Dose Optimization will include first-line and second-line melanoma, non-small cell …

braf v600e mutation
brain metastases
measurable disease
growth factor
oximetry
  • 1682 views
  • 04 Jun, 2021
  • 67 locations
Study of CAbozantinib in Combination With AtezolizumaB for Muscle-Invasive BladdEr Cancer

This is an open-label phase II study assessing the activity of cabozantinib combined with atezolizumab in patients with resectable muscle-invasive urothelial carcinoma who are ineligible for cisplatin-based therapy or decline cisplatin-based therapy. Each cycle equals 21 days. The dose of atezolizumab is 1200 mg IV flat dose every 3 weeks …

neutrophil count
metastasis
gilbert's syndrome
radical cystectomy
bladder cancer
  • 0 views
  • 22 May, 2021
  • 3 locations
Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy

Immunotherapy (checkpoint inhibitors) is approved as first and second line treatment to patients with metastatic bladder cancer. However, response rates are low and no biomarkers have yet shown

metastasis
radical cystectomy
bladder cancer
atezolizumab
carcinoma
  • 0 views
  • 27 Mar, 2021
  • 5 locations
Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer

The purpose of this study is to determine the good and bad effects of atezolizumab given in combination with a personalized cancer vaccine in patients with urothelial cancer either after surgery to remove organ where the tumor arose (for example, removal of the bladder) or for urothelial cancer that has …

bladder cancer
platelet count
atezolizumab
glomerular filtration rate
carcinoma
  • 7 views
  • 15 Mar, 2021
  • 1 location
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle invasive bladder cancer. Radiation therapy

gilbert's syndrome
radical cystectomy
RANKL
systemic therapy
atezolizumab
  • 37 views
  • 13 Jun, 2021
  • 171 locations
Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy

Patients older than 18 years, with muscle-invasive bladder cancer unfit for radical cystectomy because of age, comorbidities, and/or patient's refusal. This study is designed as a

metastasis
radical cystectomy
bladder cancer
transurethral resection
transurethral bladder excision
  • 0 views
  • 13 Jun, 2021
  • 14 locations